Experimental drug aims to replace grueling plasma treatment for dangerous blood clotting disorder
NCT ID NCT05714969
Summary
This study is testing an investigational drug called TAK-755 for adults with a rare and serious blood disorder called immune-mediated thrombotic thrombocytopenic purpura (iTTP). The main goal is to see if TAK-755 can help patients recover without needing the standard, intensive plasma exchange treatment. Participants receive the drug during their hospital stay and for about 6 weeks after, with the total study lasting around 3 months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AKH - Medizinische Universitat Wien
Vienna, 1090, Austria
-
Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino
Torino, 10126, Italy
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
Milan, 20122, Italy
-
General Hospital of Thessaloniki "G. Papanikolaou"
Thessaloniki, 57010, Greece
-
Hospital General Universitario Gregorio Maranon
Madrid, 28007, Spain
-
Hospital Universitari i Politecnic La Fe
Valencia, 46026, Spain
-
Hospital Universitario Virgen del Rocio
Seville, Sevilla, 41010, Spain
-
Hospital de Cruces
Barakaldo, Vizcaya, 48903, Spain
-
Leo Jenkins Cancer Center/ECU School of Medicine
Greenville, North Carolina, 27858, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Ohio State University
Columbus, Ohio, 43210, United States
-
Royal Liverpool University Hospital
Liverpool, Merseyside, L7 8XP, United Kingdom
-
Rutgers University
New Brunswick, New Jersey, 08901, United States
-
University College London Hospital
London, Greater London, NW1 2PG, United Kingdom
-
University of Florida - Shands
Gainesville, Florida, 32610, United States
-
University of Minnesota Clinical Research Unit
Minneapolis, Minnesota, 55455, United States
-
University of Utah Health Sciences Center
Salt Lake City, Utah, 84132, United States
-
Versiti Wisconsin, Inc.
Milwaukee, Wisconsin, 53226, United States
-
Weill Cornell
New York, New York, 10021, United States
Conditions
Explore the condition pages connected to this study.